BPG is committed to discovery and dissemination of knowledge
Featured Articles
12/15/2021 12:49:08 AM | Browse: 487 | Download: 1732
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 65311
Country Switzerland
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Review
Article Title Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?
Manuscript Source Invited Manuscript
All Author List Zeno Sparchez, Pompilia Radu, Adrian Bartos, Iuliana Nenu, Rares Craciun, Tudor Mocan, Adelina Horhat, Mihaela Spârchez and Jean‐François Dufour
Funding Agency and Grant Number
Corresponding Author Pompilia Radu, MD, PhD, Staff Physician, Department of Visceral Surgery and Medicine, Hepatology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 18, Bern 3010, Switzerland. radupompilia@yahoo.com
Key Words Hepatocellular carcinoma; Transarterial chemoembolization; Radiofrequency ablation; Microwave ablation; Systemic therapy; Immunotherapy combined treatments
Core Tip The field of hepatocellular carcinoma has become highly interesting in recent years, given the emergence of a large amount of data on immunotherapy and combination treatment strategies. In this light, the current clinical practice guidelines may appear restrictive, especially in borderline cases, which have become a significant challenge in tumor boards across the world. The current review is designed to provide an exhaustive analysis of the most notable advances in the field, focusing on combination therapies and their role in the therapeutic algorithm, with the ultimate goal of aiding clinicians to navigate the Barcelona clinic liver cancer classification maze.
Publish Date 2021-12-14 23:58
Citation Sparchez Z, Radu P, Bartos A, Nenu I, Craciun R, Mocan T, Horhat A, Spârchez M, Dufour JF. Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines? World J Gastrointest Oncol 2021; 13(12): 1896-1918
URL https://www.wjgnet.com/1948-5204/full/v13/i12/1896.htm
DOI https://dx.doi.org/10.4251/wjgo.v13.i12.1896
Full Article (PDF) WJGO-13-1896.pdf
Full Article (Word) WJGO-13-1896.docx